Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Johnson & Johnson (JNJ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow J&J's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
176.98 +3.04    +1.75%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
177.00
+0.02
+0.01%
19:36:06 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US4781601046 
CUSIP:  478160104
  • Volume: 7,457,874
  • Bid/Ask: 176.98 / 177.50
  • Day's Range: 174.05 - 177.16
J&J 176.98 +3.04 +1.75%
IndustryPharmaceuticals
SectorHealthcare
Employees

141700

Equity Type

ORD

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Contact Information

Top Executives

Name Age Since Title
Alex Gorsky 62 2009 Executive Chairman
Joaquin Duato 59 2011 CEO & Director
Anne M. Mulcahy 70 2009 Lead Independent Director
Nadja Y. West 61 2020 Independent Director
Darius E. Adamczyk 56 2022 Independent Director
D. Scott Davis 70 2014 Independent Director
Hubert Joly 63 2019 Independent Director
Ian Edward Lamert Davis 71 2010 Independent Director
A. Eugene Washington 71 2012 Independent Director
Mark B. McClellan 58 2013 Independent Director
Mary C. Beckerle 67 2015 Independent Director
Jennifer A. Doudna 58 2018 Independent Director
Mark Alan Weinberger 60 2019 Independent Director
Marillyn A. Hewson 68 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JNJ Comments

Write your thoughts about Johnson & Johnson
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
mavrox xx
mavrox xx May 18, 2022 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
vaccines are problematic. High penalties will come from lawsuits. stock markets are falling. However, the stock is going up. god *****share
Kelvin sunday
Kelvin sunday Apr 18, 2022 6:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tomorrow is earnings report . Let wait for report.. if below forcast we can short it on cfd ... Also the company is paying $99m to West Virginia..... That a negative report I guess...
David Peter
David Peter Mar 19, 2022 1:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I want to buy
diwakar rr
diwakar rr Feb 15, 2022 5:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The Fed's minutes from the January meeting, set to be released on Wednesday, will return focus to monetary policy, and the prospect of aggressive rate hikes ahead. 
YUNUS EMRE ALTUN
YUNUS EMRE ALTUN Jan 27, 2022 3:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
JnJ is buy and hold dude, enjoy divis. It grows slowly in a sustainable way
Peter Nwoko
Peter Nwoko Jan 25, 2022 8:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
thought tho that jnj will be on a good buy this season as they are about to improve on there vaccines
Financial Advisors
Financial Advisors Jan 23, 2022 6:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to buy or not?????
Hamziezar Hamzah
Hamziezar Hamzah Dec 20, 2021 2:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will JnJ Breakout @KC?
Sika Ba
Sika Ba Dec 20, 2021 2:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello
Andre Van Laer
Andre Van Laer Dec 17, 2021 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Window of (buy) opportunity just closed...
Sika Ba
Sika Ba Dec 17, 2021 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello
Andre Van Laer
Andre Van Laer Dec 17, 2021 10:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Window of (buy) opportunity just closed...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email